Altamira Therapeutics Ltd. (NASDAQ: CYTO) had some news that caught the market's eye back in 2024, as its affiliate, Altamira Medica, secured an extended ISO 13485 certification for its quality management system. This certification now includes the entire production process for their Bentrio nasal spray. Big deal? Absolutely—this stamp of approval means they've met rigorous international standards across design, development, production, and distribution.
The ISO 13485 standard is basically a gold star in the medical device sector, making it clear that products hit customer expectations and comply with regulatory demands at every stage. This certification didn't just fall from the sky; it came after a thorough audit from an independent body that checks all the boxes to ensure compliance.
Is Bentrio Ready to Fly High with Extended Certification?
Thomas Meyer, Altamira Medica's Chairman and CEO, expressed his pride in meeting these stringent requirements. The extended certification is key for their ambitious growth strategy revolving around Bentrio. They’re looking to partner with a strategic contract manufacturer and expand internationally—nothing like riding on global waves to push product sales.
Bentrio isn't just any nasal spray; it's marketed as drug-free and over-the-counter. Users apply it to create a protective gel on their nasal mucosa against airborne allergens and viruses where permitted. In clinical trials—including the NASAR study—it proved effective at reducing symptoms for seasonal allergic rhinitis compared to saline sprays. But let's not kid ourselves—just because it's effective doesn’t mean it’s flying off the shelves.
